Conditions: Breast Neoplasm
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 1
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the cardiac safety of Caelyx in patients with metastatic breast cancer who have previously received chemotherapy with anthracyclines.

Detailed description:

Arms:
arm 1: Pegylated Lyposomal Doxorubicin (Caelyx) 50 mg/m2, given for 6 cycles

Interventions: intervention 1: Pegylated Liposomal Doxorubicin
Intervention descriptions: intervention 1: Pegylated Liposomal Doxorubicin (Caelyx) IV, 50 mg/m2 once every 4 weeks for 6 cycles or until disease progression, whichever is earlier. Patients still receiving clinical benefit after a total of 6 cycles of Caelyx, may continue therapy at the discretion of the investigator.

Protocol document: